HER2-positive Recurrent / Metastatic Breast Cancer
Conditions
Brief summary
The study will assess the effect of anti-diarrhea drug Montmorillonite Power or Loperamide on the single dose pharmacokinetic parameters of pyrotinib in healthy Chinese subjects. The safety of pyrotinib alone and when co-administered with each drug will also be assessed.
Interventions
DRUGpyrotinib tablet
single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide
DRUGMontmorillonite Power
3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration
DRUGLoperamide
4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Pyrotinib alone and then combined with Montmorillonite Power or Loperamide
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions. 2. Able to complete the study as required by the protocol. 3. Healthy male and female subjects aged 18 to 45 years on the day of signing the informed consent form; appropriate proportion of subjects of different genders (no less than 3 of single gender) required in both groups A and B. 4. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within the range of 19 \ 26 kg/m2. 5. Subjects of childbearing potential and their partners have no birth plan and voluntarily take effective contraception during the course of clinical trial until 3 months after the last dose (Female subjects are also required to use highly effective non-drug contraception starting two weeks before study entry and can use contraceptives after study completion).
Exclusion criteria
1. Blood donation no less than 400 mL or have blood transfusion within 3 months of dosing. 2. History of significant hypersensitivity, intolerance, or allergy to any drug compound or known allergy to pyrotinib, montmorillonite power, loperamide or the excipients; 3. History of drug abuse in the past 5 years, or positive for drug abuse screening; 4. History of alcoholism with alcohol consumption over 14 units per week; heavy smoker; and can't abstain from smoking and alcohol during the study 5. QTcF \>470 msec for females or \>450 msec for males by 12 lead electrocardiograph; 6. Left ventricular ejection fraction (LVEF) \<50% by echocardiography 7. Significant history or clinical manifestation of any neurological, cardiovascular, renal, gastrointestinal, pulmonary, respiratory, metabolic and musculoskeletal disorder, as determined by the Investigator (or designee). 8. Any surgery within 6 months before screening; 9. Intake of hepatotoxic drugs for a long time within 6 months before screening; 10. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months; 11. Subjects who took any drugs that change liver enzymes activity within 28 days before dosing; 12. Subjects who took any prescription drugs, over-the-counter drugs or vitamins, health products or herbal medicine within 14 days before dosing; 13. Clinically significant abnormalities as determined by the Investigator (or designee) in general physical examination, vital signs, laboratory tests, etc. 14. Pregnant or lactating females 15. Positive serology test results for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or human immunodeficiency virus antibody. 16. Subjects who took any beverage or food containing grapefruit, xanthine, caffeine, or alcohol within 48 hours before dosing; strenuous exercise; or other factors which affect drug absorption, distribution, metabolism, excretion, etc 17. Subjects who need to avoid inhibiting intestinal peristalsis, such as patients with flatulence or constipation, or gastrointestinal symptoms such as diarrhea, dry mouth, abdominal distension, anorexia, gastrointestinal spasm, nausea, vomiting, as well as dizziness, headache and fatigue; 18. Those who have special requirements for diet and cannot comply with the diet and corresponding requirements provided by the trial; 19. Those who cannot tolerate venipuncture or with a history of needle-sickness and blood-sickness. 20. Those who have received a live vaccine 2 weeks prior to dosing or are scheduled to be vaccinated within 7 days after study completion. 21. Subjects who, in the opinion of the Investigator should not participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax of pyrotinib | Day 1 and Day 9 | Maximum concentration (Cmax) of pyrotinib |
| AUC of pyrotinib | Day 1 and Day 9 | Area under the plasma concentration versus time curve of pyrotinib |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters （Tmax） of pyrotinib | Day 1 and Day 9 | — |
| AEs and SAEs | From the first drug administration to 7 days after the last drug administration | Adverse events and serious adverse events |
| PK parameters （CL/F） of pyrotinib | Day 1 and Day 9 | — |
| PK parameters （Vz/F） of pyrotinib | Day 1 and Day 9 | — |
Countries
China
Outcome results
None listed